DAIC

MARCH 29, 2024

The primary effectiveness endpoint was a composite of death, heart transplant/left ventricular assist device (LVAD) implantation, HF hospitalization, outpatient HF worsening, and quality of life. and worldwide," said Neal Eigler, M.D. , CEO of V-Wave. Canada, Israel, Australia and New Zealand. million people globally.

Preserved Ejection Fraction 111

Preserved Ejection Fraction Heart Failure Quality of Life Hospital 111

European Journal of Heart Failure

NOVEMBER 11, 2024

Aims Timely referrals for transplantation and left ventricular assist device (LVAD) play a key role in favourable outcomes in patients with advanced heart failure (HF). Cardiovascular mortality, driven by sudden cardiac death, is the main reason for dying while waiting for heart transplantation (HTx).

Heart Transplant 40

Heart Transplant Transplant Heart Failure Ablation 40

Dr. Sanjay Gupta

MARCH 6, 2022

So she went back in 4 weeks and this time saw another doctor who asked her to stop the inhalers and suggested that it could be her heart and organised a chest X-ray and blood tests. Medications that improve quality of life in heart failure for example include diuretics.

Chronic Disease 40

Chronic Disease Quality of Life Heart Failure Nursing 40

Society of Thoracic Surgeons - Research

APRIL 20, 2023

Adult Cardiac Surgery Database Lead Author Title Publication Date Jacob Raphael Red Blood Cell Transfusion and Pulmonary Complications: The Society of Thoracic Surgeons Adult Cardiac Surgery Database Analysis The Annals of Thoracic Surgery January 2024 Joseph Sabik Multi-Arterial versus Single-Arterial Coronary Surgery: Ten Year Follow-up of One Million (..)

Research 52

Research Coronary Artery Bypass Graft Aortic valve Congenital 52

Society of Thoracic Surgeons - Research

APRIL 20, 2023

Program Designations Access and Publications (A&P) 1 Participant User File (PUF) 2 Task Force on Funded Research (TFR) 3 Special Projects 4 Adult Cardiac Surgery Database Lead Author Title Publication Date William Keeling 2 National Trends in Emergency Coronary Artery Bypass Grafting European Journal of Cardiothoracic Surgery October 2023 Jake (..)

Research 52

Research Coronary Artery Bypass Graft Aortic valve Congenital 52

DAIC

APRIL 1, 2025

recentlyannouncedtwo-year outcomes from the double-blind randomized placebo-controlled Phase 3 CardiAMP-HF study of its CardiAMP autologous minimally invasive cell therapy for treatingischemic heart failure in patients with reduced ejection fraction (HFrEF).Results fewer heart death equivalents; 20.9% fewer non-fatal MACCE; 44.6%

Heart Failure 59

Heart Failure Quality of Life Heart Transplant Public Health 59

European Journal of Heart Failure

DECEMBER 1, 2024

5+) support is effective in facilitating heart recovery, overall survival, and quality of life. Methods and results This single-centre retrospective study examined midterm (180 days) outcomes of patients with CS supported by Impella 5+ who achieved heart recovery. The average duration of Impella support was 10.5 ± 8 days.

Cardiogenic Shock 40

Cardiogenic Shock Heart Transplant Outcomes Transplant 40